Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, has announced the approval of equity inducement grants for six new non-officer employees. The grants consist of a total of 24,200 share options, approved by the Compensation Committee of the Board of Directors, with an effective date of July 31, 2025. These options are set at an exercise price of $30.54 per common share, matching the closing price on the grant date. The share options will vest over a period of four years, with 25% vesting after the first year and the remaining options vesting monthly thereafter. Each option has a 10-year term, aligning with the terms of the Company's 2025 Inducement Equity Incentive Plan.